167 related articles for article (PubMed ID: 34070520)
1. Reduced Serum Circulation of Cell-Free DNA Following Chemotherapy in Breast Cancer Patients.
Adusei E; Ahenkorah J; Adu-Aryee NA; Adutwum-Ofosu KK; Tagoe EA; Koney NK; Nkansah E; Aryee NA; Blay RM; Hottor BA; Clegg-Lamptey JN; Arko-Boham B
Med Sci (Basel); 2021 May; 9(2):. PubMed ID: 34070520
[TBL] [Abstract][Full Text] [Related]
2. Circulating cell-free DNA integrity as a diagnostic and prognostic marker for breast and prostate cancers.
Arko-Boham B; Aryee NA; Blay RM; Owusu EDA; Tagoe EA; Doris Shackie ES; Debrah AB; Adu-Aryee NA
Cancer Genet; 2019 Jun; 235-236():65-71. PubMed ID: 31105051
[TBL] [Abstract][Full Text] [Related]
3. Identification of the plasma total cfDNA level before and after chemotherapy as an indicator of the neoadjuvant chemotherapy response in locally advanced breast cancer.
Ma G; Wang J; Huang H; Han X; Xu J; Veeramootoo JS; Xia T; Wang S
Cancer Med; 2020 Apr; 9(7):2271-2282. PubMed ID: 32017472
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic Value of Circulating Free DNA Integrity and Global Methylation Status in Gall Bladder Carcinoma.
Kumari S; Husain N; Agarwal A; Neyaz A; Gupta S; Chaturvedi A; Lohani M; Sonkar AA
Pathol Oncol Res; 2019 Jul; 25(3):925-936. PubMed ID: 29376201
[TBL] [Abstract][Full Text] [Related]
5. [Value of the concentration and integrity of serum cell-free DNA for the clinical diagnosis of esophageal carcinoma].
Qiu YW; Shen XJ; Jin CJ; Cao XJ; Ju SQ
Zhonghua Zhong Liu Za Zhi; 2018 Dec; 40(12):905-910. PubMed ID: 30605980
[No Abstract] [Full Text] [Related]
6. Circulating cell-free DNA: a promising marker of regional lymphonode metastasis in breast cancer patients.
Agostini M; Enzo MV; Bedin C; Belardinelli V; Goldin E; Del Bianco P; Maschietto E; D'Angelo E; Izzi L; Saccani A; Zavagno G; Nitti D
Cancer Biomark; 2012; 11(2-3):89-98. PubMed ID: 23011155
[TBL] [Abstract][Full Text] [Related]
7. Circulating free DNA integrity and concentration as independent prognostic markers in metastatic breast cancer.
Cheng J; Holland-Letz T; Wallwiener M; Surowy H; Cuk K; Schott S; Trumpp A; Pantel K; Sohn C; Schneeweiss A; Burwinkel B
Breast Cancer Res Treat; 2018 May; 169(1):69-82. PubMed ID: 29340881
[TBL] [Abstract][Full Text] [Related]
8. The level and integrity of plasma circulating cell-free DNA in patients with primary multiple myeloma.
Shen Q; Cen H; Jiang J; Cong Z; Zhou Y; Huang X; Zhu L; Jiang Q; Xue C
Transl Cancer Res; 2022 Nov; 11(11):4137-4147. PubMed ID: 36523306
[TBL] [Abstract][Full Text] [Related]
9. Investigation of Efficacy Evaluation Comparison of cfDNA and CEA in Colorectal Cancer.
Yu D; An G; Xu L
Clin Lab; 2016 Oct; 62(10):1947-1953. PubMed ID: 28164530
[TBL] [Abstract][Full Text] [Related]
10. Cell-free circulating ALU repeats in serum have a prognostic value for colorectal cancer patients.
Anzinger I; Nagel D; De Toni EN; Ofner A; Philipp AB; Holdt LM; Teupser D; Kolligs FT; Herbst A
Cancer Biomark; 2023; 37(4):237-248. PubMed ID: 37302022
[TBL] [Abstract][Full Text] [Related]
11. Integrity and quantity of salivary cell-free DNA as a potential molecular biomarker in oral cancer: A preliminary study.
Rapado-González Ó; López-Cedrún JL; Lago-Lestón RM; Abalo A; Rubin-Roger G; Salgado-Barreira Á; López-López R; Muinelo-Romay L; Suárez-Cunqueiro MM
J Oral Pathol Med; 2022 May; 51(5):429-435. PubMed ID: 35416334
[TBL] [Abstract][Full Text] [Related]
12. DNA integrity as biomarker in pancreatic cyst fluid.
Utomo WK; Janmaat VT; Verhaar AP; Cros J; Lévy P; Ruszniewski P; den Berg MS; Jenster G; Bruno MJ; Braat H; Fuhler GM; Peppelenbosch MP
Am J Cancer Res; 2016; 6(8):1837-41. PubMed ID: 27648370
[TBL] [Abstract][Full Text] [Related]
13. Plasma ALU-247, ALU-115, and cfDNA Integrity as Diagnostic and Prognostic Biomarkers for Breast Cancer.
Hussein NA; Mohamed SN; Ahmed MA
Appl Biochem Biotechnol; 2019 Mar; 187(3):1028-1045. PubMed ID: 30151636
[TBL] [Abstract][Full Text] [Related]
14. Circulating breast-derived DNA allows universal detection and monitoring of localized breast cancer.
Moss J; Zick A; Grinshpun A; Carmon E; Maoz M; Ochana BL; Abraham O; Arieli O; Germansky L; Meir K; Glaser B; Shemer R; Uziely B; Dor Y
Ann Oncol; 2020 Mar; 31(3):395-403. PubMed ID: 32067681
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic Value of Serum Concentration and Integrity of Circulating Cell-Free DNA in Breast Cancer: A Comparative Study With CEA and CA15-3.
Tang Z; Li L; Shen L; Shen X; Ju S; Cong H
Lab Med; 2018 Oct; 49(4):323-328. PubMed ID: 29701836
[TBL] [Abstract][Full Text] [Related]
16. Serum DNA integrity index as a potential molecular biomarker in endometrial cancer.
Vizza E; Corrado G; De Angeli M; Carosi M; Mancini E; Baiocco E; Chiofalo B; Patrizi L; Zampa A; Piaggio G; Cicchillitti L
J Exp Clin Cancer Res; 2018 Jan; 37(1):16. PubMed ID: 29382392
[TBL] [Abstract][Full Text] [Related]
17. [Is Cell-Free DNA a Useful Biomarker for Predicting the Efficacy of Preoperative Chemotherapy for Advanced Colon Cancer?].
Iwai T; Yamada T; Sonoda H; Shinji S; Matsuda A; Yonaga K; Takeda K; Ueda K; Miyasaka T; Yoshida H
Gan To Kagaku Ryoho; 2022 Aug; 49(8):893-896. PubMed ID: 36046977
[TBL] [Abstract][Full Text] [Related]
18. Circulating plasma DNA and DNA integrity in breast cancer patients undergoing neoadjuvant chemotherapy.
Lehner J; Stötzer OJ; Fersching D; Nagel D; Holdenrieder S
Clin Chim Acta; 2013 Oct; 425():206-11. PubMed ID: 23916787
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of cell-free DNA as a diagnostic biomarker in breast cancer patients.
Khurram I; Khan MU; Ibrahim S; Saleem A; Khan Z; Mubeen M; Khawar A; Ali Q
Sci Rep; 2023 Sep; 13(1):15347. PubMed ID: 37715016
[TBL] [Abstract][Full Text] [Related]
20. The role of circulating cell-free DNA and its integrity as a biomarker for diagnosis of breast cancer using ALU (247/115) bP sequences.
Abd El Hafeez HA; Abd El Rahman MZ; Kamel TM; Rezk KM; Mohamed FM; Abdel-Hameed ZA
Egypt J Immunol; 2023 Jul; 30(3):44-55. PubMed ID: 37439529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
